Rutgers & Posch advises on IPO of uniQure NV

14 February 2014

On its recent IPO and listing on NASDAQ, Dutch life sciences company uniQure NV was represented by a team of lawyers of Rutgers & Posch lead by Hendrik Jan Schimmel and Lennaert Posch. The team also consisted of Matthijs van den Broek, Franci van Helvoirt and Miranda Gossen. Timothy Corbett and Bree Peterson of Wilmer Hale advised on US law. uniQure received tax advice from Van Campen Liem.

Jefferies, Leerink Partners and Piper Jaffray & Co. acted as underwriters for this IPO. They were represented by NautaDutilh (Petra Zijp and Jochem Polderman) and Covington & Burling (Eric Blanchard, Brian Rosenzweig and Lilit Kazangyan).

In its IPO, uniQure issued and sold 5.4 million new shares at a price of USD 17 and raised total proceeds of USD 91.8 million.

uniQure is a leader in the field of gene therapy and has developed the first and currently the only gene therapy product to receive regulatory approval in the European Union.